Medicare GLP-1 Coverage: Everything Changing in July 2026

For the first time, Medicare will cover GLP-1 medications specifically for weight loss. The Medicare GLP-1 Bridge Demonstration, announced by CMS on December 23, 2025, launches in July 2026. Here's everything you need to know.

The Program at a Glance

• •Launch date: July 2026
• •Your cost: $50/month copayment
• •Medications covered: Wegovy (semaglutide) and Zepbound (tirzepatide)
• •Negotiated manufacturer price: $245/month (paid by the program)
• •Who qualifies: Medicare Part D enrollees meeting BMI and related health condition criteria
• •Estimated eligible population: ~10% of Medicare beneficiaries

This is a significant shift. Until now, Medicare Part D explicitly excluded weight loss drugs. Coverage was only available for GLP-1s prescribed for Type 2 diabetes, cardiovascular risk reduction, or obstructive sleep apnea — not weight management alone.

How the Pricing Works

The pricing structure came from a Most-Favored-Nation deal between the Trump administration and both Novo Nordisk and Eli Lilly. Both manufacturers agreed to a net price of $245/month — roughly 75-80% below the retail list price.

For context, Wegovy lists at approximately $1,349/month and Zepbound at about $1,086/month. The $245 negotiated price represents the lowest official price point for brand-name GLP-1s anywhere in the US system.

Additionally, the Inflation Reduction Act's $2,000 annual Part D out-of-pocket cap (effective since 2025) provides a backstop — even if you use other medications, your total annual prescription spending is capped.

Eligibility Requirements

To qualify for the Medicare GLP-1 Bridge, you'll need:

• •Active Medicare Part D enrollment
• •BMI of 30 or higher, OR BMI of 27+ with at least one weight-related condition
• •Related health conditions may include Type 2 diabetes, hypertension, cardiovascular disease, sleep apnea, and others
• •Prescription from a qualifying provider

Specific enrollment details and participating pharmacies are expected to be announced by CMS in the months leading up to the July launch.

What Comes After: The BALANCE Model

The Bridge program is temporary — designed to provide immediate access while the larger BALANCE Model rolls out. BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) is a voluntary CMS demonstration that combines GLP-1 coverage with lifestyle supports.

• •Medicare Part D plans can participate starting January 2027
• •State Medicaid agencies can opt in starting May 2026
• •CMS will negotiate drug pricing on behalf of all participating plans and states
• •The program includes behavioral health, nutrition counseling, and other lifestyle components alongside medication

What to Do Now

If you're on Medicare and interested in GLP-1 treatment for weight loss, here's what you can do before July 2026:

• •Talk to your doctor about whether you're a candidate based on BMI and health conditions
• •Ensure your Medicare Part D plan is active and current
• •If you have a diabetes diagnosis, your doctor may already be able to prescribe GLP-1s under existing coverage
• •Watch for CMS announcements about specific enrollment procedures as July approaches
• •Check if your current Part D plan has announced participation in the BALANCE Model for 2027